Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α. Results of a phase I clinical trial

摘要: Nine patients with a recurrent malignant glioma were treated repeated intracavitary or intracerebroventricular injections of human recombinant interleukin-2 (rIL-2) alone in combination systemic interferon-α (IFN-α). Five received only rIL-2 and four plus subcutaneous IFN-α. Therapy was administered on Monday, Wednesday, Friday schedule for up to 10 weeks, beginning dose 10,000 IU rIL-2/injection. Doses escalated every two weeks until some toxicity apparent. The maximum amount any one patient this group 580,000 IU. Patients immunotherapy held at an dosage while IFN-α, which began 3 million IU, other week 18 IU/dose. They then that IFN-α increased 50,000 total 510,000IU 417 respectively. Repeated well-tolerated by all nine no change their functional status seen. At doses rIL-2, edema around the tumor cavity observed MRI/CT scand 3/5 clinical side-effects form somnolence headache along morbidity specifically associated location also receiving + showed progressive fatigue, muscle weakness, occasionally nausea. Two these peritumoral scan. Neither hematological abnormalities nor changes from baseline values seen blood samples patients. scans made conclusion indicated progression growth site treatment occurred Further testing is indicated.